A validation study of the new revised FIGO staging system to estimate prognosis for patients with stage IIIC endometrial cancer

被引:18
|
作者
Todo, Yukiharu [1 ]
Kato, Hidenori [1 ]
Minobe, Shinichiro [1 ]
Okamoto, Kazuhira [1 ]
Suzuki, Yoshihiro [1 ]
Konno, Yosuke [1 ]
Takeda, Mahito [2 ]
Watari, Hidemichi [2 ]
Kaneuchi, Masanori [2 ]
Sakuragi, Noriaki [2 ]
机构
[1] Natl Hosp Org, Hokkaido Canc Ctr, Div Gynecol Oncol, Shiroishi Ku, Sapporo, Hokkaido 0030804, Japan
[2] Hokkaido Univ, Sch Med, Dept Obstet & Gynecol, Sapporo, Hokkaido 060, Japan
关键词
Endometrial cancer; Lymphadenectomy; Surgical staging; Prognosis; PARAAORTIC LYMPHADENECTOMY; NODE DETECTION; CARCINOMA;
D O I
10.1016/j.ygyno.2010.12.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. The aim of this study was to validate the role of the new FIGO staging system for estimating prognosis for patients with stage IIIC endometrial cancer. Methods. A total of 93 cases with stage IIIC were entered in this study and classified into three groups: one group of patients who underwent pelvic lymphadenectomy (PLX) and para-aortic lymphadenectomy (PALX) and who were for positive for pelvic node metastasis (PLNM) and negative for para-aortic node metastasis (PANM) (Group 1), one group of patients who underwent PLX alone and were positive for PLNM (Group 2) and one group of patients who underwent PLX and PALX and were positive for PANM (Group 3). Information on clinicopathologic findings and treatments was obtained from medical charts. Cox regression analysis was used to select prognostic factors. Results. The 5-years survival rates were 89.3% in Group 1, 46.5% in Group 2 and 59.9% in Group 3. The overall survival rate in Group 1 was significantly better than that in Group 2 (p = 0.0001) and Group 3 (p = 0.0016). No significant difference in overall survival was found between Group 2 and Group 3. Age, number of metastatic lymph nodes, type of lymphadenectomy and type of adjuvant therapy were significantly and independently related to overall survival. Only when patients received PALX, PANM was a prognostic risk factor. Conclusion. Sub-classification of stage IIIC would be functional for estimating prognosis in the revised FIGO staging system. Systematic lymphadenectomy including PALX has therapeutic significance for patients with stage IIIC endometrial cancer. Prognosis of patients with stage IIIC endometrial cancer would depend much more on application of lymphadenectomy including PALX than nodal status. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:126 / 130
页数:5
相关论文
共 50 条
  • [31] The revised 2014 FIGO staging system for epithelial ovarian cancer: Is a subclassification into FIGO stage IVA and IVB justified?
    Ataseven, Beyhan
    Harter, Philipp
    Grimm, Christoph
    Heitz, Florian
    Heikaus, Sebastian
    Traut, Alexander
    Kahl, Annett
    Kurzeder, Christian
    Prader, Sonia
    du Bois, Andreas
    GYNECOLOGIC ONCOLOGY, 2016, 142 (02) : 243 - 247
  • [32] Analysis of Patients With Stage IIIC Endometrial Cancer
    Turan, Taner
    Ureyen, Isin
    Duzguner, Ipek
    Ozkaya, Enis
    Tasci, Tolga
    Karalok, Alper
    Boran, Nurettin
    Kose, M. Faruk
    Tulunay, Gokhan
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (06) : 1033 - 1041
  • [33] A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System Treated with Definitive Chemoradiotherapy
    Liu, X.
    Hou, X.
    Hu, K.
    Zhang, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E327 - E327
  • [34] Does the FIGO 2009 Endometrial Cancer Staging System More Accurately Correlate With Clinical Outcome in Different Histologies? Revised Staging, Endometrial Cancer, Histology
    Page, Brandi R.
    Pappas, Lisa
    Cooke, Ellen Ware
    Gaffney, David K.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2012, 22 (04) : 593 - 598
  • [35] Lymphadenectomy increases the prognostic value of the revised 2009 FIGO staging system for endometrial cancer: A multi-center study
    Kim, H. S.
    Kim, H. Y.
    Park, C. Y.
    Lee, J. M.
    Lee, J. K.
    Cho, C. H.
    Kim, S. M.
    Kim, J. W.
    EJSO, 2012, 38 (03): : 230 - 237
  • [36] VALIDATION OF REVISED FIGO STAGING SYSTEM IN STAGE IC MUCINOUS EPITHELIAL OVARIAN CANCER(MEOC) STAGING SYSTEM TO IDENTIFY ITS CLINICAL IMPACT OF ON STAGE IC MEOC.
    Cho, Y.
    Jung, P.
    Lee, S.
    Park, J.
    Suh, D.
    Kim, D.
    Kim, J.
    Kim, Y.
    Kim, Y.
    Nam, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 412 - 412
  • [37] Utility of the revised FIGO2023 staging with molecular classification in endometrial cancer
    Kobayashi-Kato, Mayumi
    Fujii, Erisa
    Asami, Yuka
    Ahiko, Yuka
    Hiranuma, Kengo
    Terao, Yasuhisa
    Matsumoto, Koji
    Ishikawa, Mitsuya
    Kohno, Takashi
    Kato, Tomoyasu
    Shiraishi, Kouya
    Yoshida, Hiroshi
    GYNECOLOGIC ONCOLOGY, 2023, 178 : 36 - 43
  • [38] The new FIGO staging system for endometrial cancer: Is the paradigm shift clinically feasible?
    Betella, Ilaria
    De Vitis, Luigi Antonio
    Calidona, Carmelo
    Multinu, Francesco
    Colombo, Nicoletta
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2024, 164 (01) : 364 - 365
  • [39] Comparative performance of the new versus old FIGO staging system for endometrial cancer
    Lewin, S.
    Herzog, T.
    Medel, N. Barrena
    Deutsch, I.
    Sun, X.
    Burke, W.
    Wright, J.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S6 - S7
  • [40] Chemotherapy (CT) with radiotherapy versus CT alone for FIGO Stage IIIc endometrial cancer
    Matsuura, M.
    Suzuki, T.
    Morishita, M.
    Tanaka, R.
    Ito, E.
    Saito, T.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2009, 30 (01) : 40 - 44